Posted by Michael Wonder on 09 Sep 2016
TGA publishes AusPAR for Lenvima (lenvatinib mesylate)
9 September 2016 - The TGA has published an AusPAR for Eisai's vascular endothelial growth factor inhibitor inhibitor.
Lenvima was approved by the TGA on 21 January 2016 for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer.
